FeNO guidelines vary worldwide—this article compares UK and international clinical practices.
Sponsored Content by NObreathReviewed by Andrea SalazarJul 28 2025 Fractional exhaled Nitric Oxide is widely used in both primary and secondary care settings across the world. Many regions recommend incorporating FeNO-guided management into their clinical standards, and resulting FeNO-related guidelines can vary across the UK and other countries.
The following explores and compares these approaches. Guidelines NICE, BTS, and SIGN guidelines: In November 2024, the National Institute for Health and Care Excellence published the most significant update to UK guidelines in recent years. Jointly released with the British Thoracic Society and the Scottish Intercollegiate Guidelines Network , the new guidelines looked more closely at asthma diagnosis, monitoring, and chronic asthma management.1 Prior to this, NICE, BTS, and SIGN published their guidelines independently. The newly published guidelines harmonize standards across the board and introduce considerable changes to asthma care techniques, including FeNO testing. This is an objective airway inflammation test that supports asthma diagnosis and management. ERS guidelines: In 2022, the European Respiratory Society updated its guidelines for the diagnosis of adult asthma. In patients over 18 years of age with suspected asthma, where initial spirometry and bronchodilator reversibility testing have not confirmed a diagnosis, ERS suggests measuring FeNO as part of the diagnostic work-up. This is a conditional recommendation based on moderate-quality evidence.2 DGP guidelines: The German Respiratory Society is the largest and oldest medical professional organization for respiratory disorders. Its most recent guidelines on asthma, titled ‘S2K guidelines for specialist diagnosis and therapy of asthma,’ were published in 2023. In these guidelines, FeNO is identified as a fundamental component of specialist asthma diagnostics.3 ATS guidelines: In 2011, the American Thoracic Society developed guidance on interpreting FeNO testing in adults and children . The most recent American Thoracic Society update on using FeNO to guide asthma treatment was published in 2021. It strongly recommends the use of FeNO testing in addition to regular care procedures for the management of asthma in patients.4,5 In response to the ATS guidelines, the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology , published a joint statement in 2012, saying, “We formally recognize and support the 2011 ATS Clinical Practice Guideline on the Interpretation of Exhaled Nitric Oxide for Clinical Applications”.6 GINA guidelines:7,8 The Global Initiative for Asthma works with clinicians, patient groups, and public health bodies around the world to reduce asthma prevalence, morbidity, and mortality. Its 2024 guidelines highlight FeNO as a useful biomarker for both diagnosing and managing the condition, with recommended ppb levels to support diagnosis. While no specific cut-off values are given for children, GINA acknowledges FeNO’s role in guiding treatment decisions. Reimbursement for FeNO: Reimbursement policies for FeNO testing differ by country. In England, practices aim to maximize Quality and Outcomes Framework points to sustain practice income and cover costs such as the purchase and maintenance of equipment, including FeNO devices.9 Currently, the QoF requirements for asthma diagnosis include spirometry and an additional test, such as FeNO, bronchodilator reversibility, or measures of variability. Recent updates to the BTS/SIGN/NICE guidelines will change the requirements, with practices now expected to carry out at least one objective test to support an asthma diagnosis. For adults, this could include FeNO or blood eosinophil measurement, while for children the first test should be FeNO. In Germany, FeNO testing is endorsed in the national asthma guidelines. But, it is not reimbursed by Statutory Health Insurance in primary care settings. However, in North America, Medicare and Medicare Advantage plans provide reimbursement for FeNO testing if a healthcare professional deems it medically necessary.10 The importance of guidelines: The use of asthma diagnosis and management guidelines in the application of FeNO is essential worldwide. They help to ensure standardized, evidence-based asthma management tailored to diverse healthcare infrastructures and patient demographics. By empowering medical professionals to make informed decisions, these guidelines enhance the precision of asthma diagnosis and treatment. Established guidelines help ensure consistent treatment, reduce misdiagnosis, control healthcare costs, and improve patient outcomes. In addition to the countries already discussed, many others, including Japan, Italy, China, France, Mexico, Spain, Malaysia, and Australia, have also developed their own national guidelines.Management:ATS guidelines: Diagnosis:FeNO testing with the NObreath®: Regular FeNO measurements indicate levels of airway inflammation, enabling healthcare professionals to personalize treatment plans by titrating ICS dosing and evaluating patient adherence to treatment. For more than 48 years, Bedfont® Scientific Limited has specialized in the design and production of breath analysis medical devices. Using cutting-edge technology, Bedfont® provides innovative and affordable medical devices to enhance accessibility and healthcare standards around the world. Bedfont® manufactures the NObreath® FeNO device, a non-invasive breath testing instrument used to measure airway inflammation for asthma diagnosis and management.References: About Bedfont® Scientific Ltd Bedfont® Scientific has specialised in the design and manufacture of exhaled breath and gas monitoring instruments since 1976. For medical gas monitoring, their Medi-Gas Check medical pipeline testing range verifies not only the quantity but also quality of gas administered to patients. Bedfont's breath analysers include carbon monoxide monitors such as the Smokerlyzer®, used for smoking cessation, and the ToxCO®, used by emergency services, to diagnose CO poisoning. The NObreath® FeNO monitor provides accurate analysis of airway inflammation for the control of asthma, and the Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances. Quick and non-invasive, breath analysis is the new blood test. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wimbledon betting guide: Our tips ahead of 2025’s third tennis majorWimbledon stands tall as one of the four Grand Slams in tennis. This year marks the 138th edition of the iconic event held at SW19, with the 2025 tour
Read more »
Our guide to every team at Women's Euro 2025, predictions and players to watchHow far England and Wales can go, who are the favourites to win it and the stars who will shape this summer's tournament in Switzerland
Read more »
Scrublands: Silver season 2 cast, filming locations and episode guideInvestigative journalist Martin Scarsden is on the trail of a murderer but this time closer to home
Read more »
How FeNO testing supports asthma diagnosis and ongoing careLearn how FeNO testing supports accurate asthma diagnosis and long-term management.
Read more »
Addressing inequality in asthma treatment and diagnosisDiscover how expanding FeNO testing can help make asthma care more equitable.
Read more »
The importance of early asthma detection in children’s healthLearn how early asthma diagnosis with FeNO testing can improve children’s health.
Read more »